A combination of thalidomide and arsenic trioxide is effective and well tolerated in patients with myelodysplastic syndromes

Leukemia Research

Volumn 36, Issue 6, 2012, Pages 715-719

  Wei, Wei ^a   Zhou, Fan ^a   Zhang, Yizi ^a   Guo, Lieping ^a   Shi, Haotian ^a   Hou, Jian ^a,b  

^a Shanghai Zhabei District Central Hospital   (China)

^b SECOND MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Arsenic trioxide; Myelodysplastic syndromes; Thalidomide; Toxicity; Treatment

Indexed keywords

ARSENIC TRIOXIDE; RECOMBINANT ERYTHROPOIETIN; THALIDOMIDE;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; BONE MARROW SUPPRESSION; CLINICAL ARTICLE; COMBINATION CHEMOTHERAPY; CONGESTIVE HEART FAILURE; CONSTIPATION; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG ERUPTION; DRUG FATALITY; DRUG FEVER; DRUG RESPONSE; DRUG TOLERABILITY; ERYTHROCYTE TRANSFUSION; FEMALE; FLUID RETENTION; HUMAN; HUMAN TISSUE; INFECTION; MALE; MONOTHERAPY; MYELODYSPLASTIC SYNDROME; NEUROPATHY; NEUTROPENIA; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PRURITUS; QT PROLONGATION; REFRACTORY ANEMIA; REFRACTORY ANEMIA WITH EXCESS BLASTS; REFRACTORY CYTOPENIA WITH MULTILINEAGE DYSPLASIA; REMISSION; SIDE EFFECT; SINUS BRADYCARDIA; THROMBOCYTOPENIA; UNSPECIFIED SIDE EFFECT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ARSENICALS; FEMALE; HUMANS; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; OXIDES; PILOT PROJECTS; SURVIVAL ANALYSIS; THALIDOMIDE; TREATMENT OUTCOME;

EID: 84862780070     PISSN: 01452126     EISSN: 18735835     Source Type: Journal    
DOI: 10.1016/j.leukres.2011.12.023     Document Type: Article

References (32)

1. Malcovati L., Nimer S.D. Myelodysplastic syndromes: diagnosis and staging. Cancer Control 2008, 15:4-13.
2. Barzi A., Sekeres M.A. Myelodysplastic syndromes: a practical approach to diagnosis and treatment. Cleve Clin J Med 2010, 77:37-44.
3. Solary E., Fontenay M. Myelodysplastic syndromes. Rev Prat 2010, 60:1408-1412.
4. List A.F. Treatment strategies to optimize clinical benefit in the patient with myelodysplastic syndromes. Cancer Control 2008, 15:29-39.
5. Faderl S., Kantarjian H.M. Novel therapies for myelodysplastic syndromes. Cancer 2004, 101:226-241.
6. Greenberg P.L., Attar E., Bennett J.M., et al. NCCN Clinical Practice Guidelines in Oncology: myelodysplastic syndromes. J Natl Compr Canc Netw 2011, 9:30-56.
7. Grossi A., Liumbruno G.M. New drugs in the treatment of myelodysplastic syndromes: are they changing the role of transfusion support?. Blood Transfus 2008, 6:191-198.
8. Bowen D., Culligan D., Jowitt S., et al. Guidelines for the diagnosis and therapy of adult myelodysplastic syndromes. Br J Haematol 2003, 120:187-200.
9. Hellström-Lindberg E. Efficacy of erythropoietin in the myelodysplastic syndromes: a meta-analysis of 205 patients from 17 studies. Br J Haematol 1995, 89:67-71.
10. Hellström-Lindberg E., Negrin R., Stein R., et al. Erythroid response to treatment with G-CSF plus erythropoietin for the anaemia of patients with myelodysplastic syndromes: proposal for a predictive model. Br J Haematol 1997, 99(November (2)):344-351.
11. Casadevall N., Durieux P., Dubois S., et al. Health, economic, and quality-of-life effects of erythropoietin and granulocyte colony-stimulating factor for the treatment of myelodysplastic syndromes: a randomized, controlled trial. Blood 2004, 104:321-327.
12. Broliden P.A., Dahl I.M., Hast R., et al. Antithymocyte globulin and cyclosporine A as combination therapy for low-risk non-sideroblastic myelodysplastic syndrome. Haematologica 2006, 91:667-670.
13. Lim Z.Y., Killick S., Germing U., et al. Low IPSS score and bone marrow hypocellularityin MDS patients predict hematological responses to antithymocyte globulin. Leukemia 2007, 21:1436-1441.
14. - blood cells predicts platelet response. Int J Hematol 2007, 86:150-157.
15. List A., Kurtin S., Roe D.J., et al. Efficacy of lenalidomide in myelodysplastic syndromes. N Engl J Med 2005, 352:549-557.
16. Adès L., Boehrer S., Prebet T., et al. Efficacy and safety of lenalidomide in intermediate-2 or high-risk myelodysplastic syndromes with 5q deletion: results of a phase 2 study. Blood 2009, 113:3947-3952.
17. Lyons R.M., Cosgriff T.M., Modi S.S., et al. Hematologic response to three alternative dosing schedules of azacitidine in patients with myelodysplastic syndromes. J Clin Oncol 2009, 27:1850-1856.
18. Fenaux P., Mufti G.J., Hellstrom-Lindberg E., et al. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. Lancet Oncol 2009, 10:223-232.
19. Steensma D.P., Baer M.R., Slack J.L., et al. Multicenter study of decitabine administered daily for 5 days every 4 weeks to adults with myelodysplastic syndromes: the alternative dosing for outpatient treatment (ADOPT) trial. J Clin Oncol 2009, 27:3842-3848.
20. Anargyrou K., Vassilakopoulos T.P., Angelopoulou M.K., et al. Incorporating novel agents in the treatment of myelodysplastic syndrome. Leuk Res 2010, 34:6-17.
21. Musto P. Thalidomide therapy for myelodysplastic syndromes: current status and future perspectives. Leuk Res 2004, 28:325-332.
22. Yasui K. Thalidomide as immunomodulatory drug: pharmacological actions and its indications. Nihon Rinsho Meneki Gakkai Kaishi 2010, 33:229-233.
23. Raza A., Meyer P., Dutt D., et al. Thalidomide produces transfusion independence in long standing refractory anemias of patients with myelodysplastic syndromes. Blood 2001, 98:958-965.
24. Raza A., Lisak L., Billmeier J., et al. Phase II study of topotecan and thalidomide in patients with high-risk myelodysplastic syndrome. Leuk Lymphoma 2006, 47:433-440.
25. Emadi A., Gore S.D. Arsenic trioxide - an old drug rediscovered. Blood Rev 2010, 24:191-199.
26. Izdebska M., Grzanka A., Szczepański M.A., Litwiniec A. Selected mechanisms of the therapeutic effect of arsenic trioxide in cancer treatment. Postepy Hig Med Dosw 2008, 62:463-467.
27. Sekeres M.A. New data with arsenic trioxide in leukemias and myelodysplastic syndromes. Clin Lymphoma Myeloma 2007, 8:S7-S12.
28. List A., Beran M., DiPersio J., et al. Opportunities for Trisenox (arsenic trioxide) in the treatment of myelodysplastic syndromes. Leukemia 2003, 17:1499-1507.
29. Schiller G.J., Slack J., Hainsworth J.D., et al. Phase II multicenter study of arsenic trioxide in patients with myelodysplastic syndromes. J Clin Oncol 2006, 24:2456-2464.
30. Raza A., Buonamici S., Lisak L., Tahir S., Li D., Imran M. Arsenic trioxide and thalidomide combination produces multi-lineage hematological responses in myelodysplastic syndromes patients, particularly in those with high pre-therapy EVI1 expression. Leuk Res 2004, 28:791-803.
31. Vardiman J.W. The World Health Organization (WHO) classification of tumors of the hematopoietic and lymphoid tissues: an overview with emphasis on the myeloid neoplasms. Chem Biol Interact 2010, 184:16-20.
32. Cheson B.D., Greenberg P.L., Bennett J.M., et al. Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia. Blood 2006, 108:419-425.